BASELINE BLOOD EOS ≥300 CELLS/µL & MEDIUM ICS DOSE > QUEST
(POST HOC ANALYSIS)

Severe exacerbations through Week 52

71%
reduction in severe exacerbationse through Week 52

with DUPIXENT 300 mg Q2W + SOC (n=129) vs placebo + SOC (n=61) (rate ratio: 0.29 [95% CI:
0.17, 0.51]) (baseline blood EOS ≥300 cells/μL, QUEST, post hoc analysis)2,4,5

  • 73% reduction in severe exacerbations through Week 52 with DUPIXENT 200 mg Q2W + SOC (n=134) vs placebo + SOC (n=68) (rate
    ratio: 0.27 [95% CI: 0.15, 0.48]) (baseline blood EOS ≥300 cells/μL, QUEST, post hoc analysis)2,4,5

Results are descriptive. Definitive conclusions cannot be made as this was a post-hoc analysis. There are limitations on sample size and data
were not multiplicity controlled.

eSevere exacerbations were defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or hospitalization
or ED visit due to asthma that required systemic corticosteroids.1

BASELINE BLOOD EOS ≥300 CELLS/µL & MEDIUM ICS DOSE > TRAVERSE OLE STUDY (POST HOC ANALYSIS)

Severe exacerbations through Week 96

ZERO
exacerbations in 70% of patients from QUEST in Year 3

(Week 96) when treated with
DUPIXENT 300 mg Q2W + SOC
(n=215) for 52 weeks in QUEST
and
continued with DUPIXENT
300 mg Q2W + SOC in the OLE
period (baseline blood EOS ≥300
cells/μL,
TRAVERSE OLE study,
post hoc analysis)2,4

Results are descriptive. Definitive conclusions cannot be made as this was a post hoc analysis of open-label extension data.

Data were not multiplicity controlled and there are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of
nonresponders.

Patients with higher short-acting beta agonist use (3+ canisters/
year)
were more likely to experience 1+ severe exacerbation requiring an
HCP visit or hospitalization6,f

fBased on observational analyses of SABA use IN Asthma (SABINA)
datasets involving patients from Europe and North America.

Consider DUPIXENT sooner
for your appropriate
asthma patients on
medium ICS dose + one
or more controller

ED, emergency department; EOS, eosinophils; ICS,
inhaled corticosteroid; ITT, intention-to-treat; OLE,
open‑label extension; Q2W, once every 2 weeks; SOC,
standard of care.

Consider DUPIXENT sooner for your appropriate asthma patients on medium ICS dose + one or more controller

ED, emergency department; EOS, eosinophils; ICS, inhaled corticosteroid; ITT, intention-to-treat; OLE, open‑label extension; Q2W, once every 2 weeks; SOC, standard of care.